Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Get Thin MD vs ShapeIn Rx

Get Thin MD
Graded #185

Higher grade

vs+6.300000000000004
ShapeIn Rx
Graded #325

Lower grade

The verdict

Get Thin MD takes it — 66.7/100 to 60.4/100.

Get Thin MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Get Thin MD is a nationwide async telehealth platform offering compounded semaglutide and tirzepatide injections plus brand-name Ozempic and Zepbound where appropriate, alongside a broader wellness menu…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueShapeIn Rx +24
50
74
Dose & formulationGet Thin MD +20
77
57
Clinical oversightGet Thin MD +30
90
60
Labs & monitoringGet Thin MD +3
55
52
FulfillmentGet Thin MD +29
91
62
Contract termsShapeIn Rx +21
20
41
Get Thin MD · left barShapeIn Rx · right bar

The numbers

MetricGet Thin MDShapeIn Rx
WeighScore66.7/10060.4/100
GradeCC
Scorecard rank#185#325
Semaglutide$199/mo (compounded)$199/mo (compounded)
Tirzepatide$299/mo (compounded)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Get Thin MD

Graded #185 · C

Strengths

  • 3-month compounded semaglutide at $169/mo is among the lowest ongoing prices in the category
  • Price-lock promise — same price every dose, no hidden fees
  • Both compounded and brand-name options on one platform (sema, tirz, plus Ozempic and Zepbound)
  • Nationwide availability with async evaluation — no in-person visit
  • Broader wellness menu (sermorelin, NAD+, HRT, hair loss) lets you consolidate protocols

Where it loses points

  • Compounded medications aren't FDA-approved and lack the review of brand-name GLP-1s
  • Pharmacy partners not named — no way to verify the compounding source or batch testing
  • Claims nationwide coverage but publishes no state list — confirm at intake
  • Headline results (9.6 lbs in 30 days) come from self-reported patient data, not a trial
  • Wide wellness funnel may steer you toward non-weight-loss protocols
ShapeIn Rx

Graded #325 · C

Strengths

  • One of the few telehealth providers offering compounded liraglutide as a daily alternative to weekly injections
  • Semaglutide is compounded with B12, and the combination is stated plainly
  • Publishes a street address and a staffed phone line with hours
  • States openly that telemedicine is limited to jurisdictions where its providers are licensed, rather than claiming all 50
  • LegitScript certification verified against the issued seal, not just the badge

Where it loses points

  • Advertises Trusted by 150k Americans and Excellent 4.8 with 150k happy customers, and neither figure is attributable to a verifiable review profile
  • No state list is published, only a statement that coverage is limited and a note that partner pharmacies may operate in all 50 states
  • The struck-through $199 next to $149 on the homepage reads as a discount but the two prices are different medications
  • Claims No Hidden Fees and No Monthly Membership while the Terms state subscriptions automatically renew
  • No compounding pharmacy is named, only US-Certified Pharmacy

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard